Fibrinogen Concentrate (Human)(Fibrinogen Concentrate (Human)) - 药物靶点：Fibrinogen_在研适应症：出血_专利_临床

概要

基本信息

药物类型

血液提取物

别名

Haemocomplettan、Riastap

靶点

Fibrinogen

作用方式

刺激剂

作用机制

纤维蛋白原刺激剂

治疗领域

其他疾病

在研适应症

出血

非在研适应症

纤维蛋白原缺乏血症主动脉瘤冠心病+ [3]

原研机构

ProMetic Biotherapeutics Ltd.

在研机构

CSL Behring GmbH

非在研机构

CSL Behring LLC

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2009-01-16),

出血

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

42

项与 Fibrinogen Concentrate (Human) 相关的临床试验

NCT06582420

/ Not yet recruitingN/AIIT

Pre-hospital Administration of Fibrinogen Concentrate in Patients With Suspected Trauma-Induced Coagulopathy (PAF-TIC)

A prospective, randomized controlled trial of fibrinogen concentrate (FC) plus standard of care versus standard of care alone in adult trauma patients with major bleeding or presumed major bleeding is developed to evaluate the efficacy and safety of prehospital administration of FC in trauma patients with suspected hypofibrinogenemia and active bleeding or presumed to be bleeding.
The main endpoints are:
1. Plasma fibrinogen levels in the first blood sample drawn at the patient's arrival at the trauma room and/or similar emergency bay dedicated to trauma and reanimation above the critical threshold of 2.0 g/l. As fibrinogen decreases early in trauma, its deficiency predicts massive bleeding and death.
2. Administration feasibility of FC within the prehospital setting.
Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC.

开始日期2025-01-01

申办/合作机构-

CTRI/2024/09/073878

/ Not yet recruitingN/AIIT

Evaluation of the effect of fibrinogen on peripartum hemorrhage in Placenta accreta spectrum (PAS) disorders, a double blind randomized controlled trial. - NIL

开始日期2024-09-24

申办/合作机构-

NCT05449834

/ Recruiting临床3期IIT

Fibrinogen Early In Severe Trauma StudY II

Annually over 7000 Australians are treated for severe trauma. Haemorrhage secondary to severe trauma is a major cause of potentially preventable death and poor outcomes in Australian adults. Severe trauma may trigger changes in blood clotting mechanisms and factor levels leading to inhibition of clot formation and reduced clot strength. This results in the inability of the severely injured trauma patient to form adequate clots to help stop bleeding. There is good evidence to suggest the loss of clotting factors during haemorrhage is associated with worse outcomes and it is thought the early replacement of these factors may reduce bleeding and improve patient outcomes. Fibrinogen is a key clotting factor that helps bind clots together and early fibrinogen replacement may improve outcomes.
Currently fibrinogen is replaced using cryoprecipitate, a blood product made from blood donated by healthy donors which is a precious resource. It can take a significant amount of time to administer as it is frozen and stored in the blood bank. Timely administration of cryoprecipitate is difficult as it requires thawing prior to transfusion. The large doses of cryoprecipitate used in traumatic haemorrhage can put strain on local blood banks in supplying requested units in a timely manner. Additionally, the widely dispersed population of Australia introduces logistic challenges to the maintenance of adequate cryoprecipitate stocks to individual hospital blood banks, especially in remote regions. However, cryoprecipitate contains a number of other coagulation factors (not just fibrinogen) that may be instrumental in clot formation and resistance to fibrinolysis.
Fibrinogen concentrate is an alternative product used to assist in blood clotting. It is a dry powder form of fibrinogen and can be reconstituted at the bedside and given quickly. The use of a fibrinogen factor concentrate with a long shelf life that is easy to use has significant implications for both large urban metropolitan areas and remote isolated communities.
The timing and mode of fibrinogen replacement in traumatic haemorrhage has implications for patient outcomes, blood product availability, costs and the national blood supply. Despite the importance of fibrinogen replacement in traumatic haemorrhage, there have been no clinical trials powered for clinical outcomes directly comparing fibrinogen concentrate and cryoprecipitate. FEISTY II will evaluate the efficacy, safety and cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate in trauma patients with major haemorrhage.
FEISTY II is a phase III randomised trial which will enrol 850 patients from Australian and New Zealand major trauma centres, with a primary patient outcome of days alive out of hospital at day 90 after injury. Severely injured trauma patients who require blood transfusion and have evidence of low fibrinogen levels will be randomised to receive either fibrinogen concentrate or standard care with cryoprecipitate

开始日期2022-11-21

申办/合作机构

Australian and New Zealand Intensive Care Research Centre

[+2]

100 项与 Fibrinogen Concentrate (Human) 相关的临床结果

登录后查看更多信息

100 项与 Fibrinogen Concentrate (Human) 相关的转化医学

登录后查看更多信息

100 项与 Fibrinogen Concentrate (Human) 相关的专利（医药）

登录后查看更多信息

455

项与 Fibrinogen Concentrate (Human) 相关的文献（医药）

2026-02-01·JOURNAL OF CLINICAL ANESTHESIA

Impact of implementing a thromboelastometry-guided transfusion strategy on fibrinogen supplementation and transfusion in women with postpartum hemorrhage

Article

作者: Desgranges, François-Pierrick ; Bouvet, Lionel ; Chamouard, Valérie ; Zheng, Anne ; Nougier, Christophe ; Vacheron, Charles-Hervé

STUDY OBJECTIVE:

Coagulopathy is a key determinant of maternal prognosis in case of postpartum hemorrhage. We sought to assess the impact of implementing a thromboelastometry-based coagulopathy management protocol on fibrinogen concentrate use and transfusion strategies.

DESIGN:

Retrospective study.

SETTING:

Tertiary care obstetric unit, university hospital, Lyon, France.

PATIENTS:

Adult women with postpartum hemorrhage (≥500 mL blood loss within 24 h postpartum) at a gestational age ≥ 22 weeks.

INTERVENTIONS:

Three distinct periods were analyzed: Period 1 (2016-2018, no viscoelastic test available), Period 2 (2019-2020, thromboelastometry available in our maternity unit) and Period 3 (2021-2023, implementation of a thromboelastometry-based coagulopathy management protocol).

MEASUREMENTS:

The primary endpoint was the proportion of patients receiving fibrinogen concentrate in each period. Secondary endpoints were the proportions of patients transfused with blood products within the first 24 h in each period. Adjusted odds ratios (aOR) for each outcome were estimated using bidirectional stepwise regression in a final model that included 12 preselected confounders.

MAIN RESULTS:

A total of 3899 patients were analyzed. Period 3 and Period 2 were independently associated with significantly lower odds of fibrinogen concentrate administration compared to Period 1. The aOR was 0.19 (95 %CI: 0.14 to 0.28) for Period 3 and 0.70 (95 %CI: 0.50 to 0.98) for Period 2. Period 3 was also independently associated with significantly lower odds of transfusion of red blood cells (aOR = 0.25 [95 %CI: 0.19 to 0.33]), fresh frozen plasma (aOR = 0.17 [95 %CI: 0.09 to 0.33]) and platelet concentrates (aOR = 0.23 [95 %CI: 0.08 to 0.62]) compared to Period 1. The frequency of massive postpartum hemorrhage (≥2500 mL) did not change significantly across the three periods.

CONCLUSIONS:

Implementing a thromboelastometry-guided protocol was associated with significantly reduced use of fibrinogen concentrate, red blood cells, fresh frozen plasma, and platelet concentrates, without increasing the risk of progression to massive hemorrhage. Further assessments of maternal outcomes and cost-effectiveness are required.

2026-02-01·INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA

Acute obstetric coagulopathy without severe postpartum haemorrhage following medical termination of pregnancy presenting as gingival bleeding: a case report

Article

作者: Dhadda, A ; Metodiev, Y ; Thomas, G

Postpartum haemorrhage is a leading cause of maternal morbidity and mortality worldwide - rarely this is complicated by coagulopathy. Our understanding of the mechanisms of acute obstetric coagulopathy remains uncertain. This report aims to highlight the importance of its early recognition, diagnosis and management. We report a case of acute obstetric coagulopathy potentially exacerbating postpartum haemorrhage following medical termination of pregnancy at 23 weeks gestation. We describe an unusual clinical presentation with gingival bleeding and evidence of hyperfibrinolysis beyond that of previously described cases. Despite the extreme coagulation abnormalities, the clinical situation did not proceed to severe postpartum haemorrhage owing to early suspicion and recognition of acute obstetric coagulopathy, as well as targeted treatment with fibrinogen concentrate and antifibrinolytics. The patient developed mild acute kidney injury which recovered spontaneously prior to discharge. This case highlights the need for better understanding of acute obstetric coagulation and its underlying mechanisms. This specific coagulation disorder has been described relatively recently for the first time and has never been reported in patients undergoing a medical termination of pregnancy in the second trimester. Further research is needed to improve our understanding on its mechanisms and triggers to potentially inform optimal management.

2026-02-01·INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA

Availability and use of fibrinogen concentrate in labor and delivery units in North America with the Society for Obstetric Anesthesia and Perinatology (SOAP) center of excellence designation: a study survey (2023)

Article

作者: Peralta, F M ; Samworth, A G ; Bhat, A D ; Lange, E M ; McCarthy, R J ; Battrell, J R

BACKGROUND:

Postpartum hemorrhage is the leading cause of maternal mortality worldwide and is often complicated by hypofibrinogenemia, increasing the risk of severe hemorrhage. Fibrinogen concentrate may offer several advantages over cryoprecipitate for rapid fibrinogen replacement, but data on its availability and use in obstetric units are limited.

METHODS:

An IRB-approved electronic survey was distributed to all 70 Society for Obstetric Anesthesia and Perinatology (SOAP) Centers of Excellence (COE) in the United States and Canada. Responses were collected over six weeks, with three reminders.

RESULTS:

Twenty-eight centers (40%) responded. Annual delivery volumes ranged from <2,500 (14%) to >6,000 (26%). Fibrinogen concentrate was available in 75% of the centers, but only 17 (61%) had it on the Labor and Delivery Unit. Delivery volume did not correlate with institutional (ρ = -0.11, P = 0.56) or Labor and Delivery Unit (ρ = 0.03, P = 0.89) availability of fibrinogen concentrate. In centers with availability on the Labor and delivery Unit, 94% incorporated it in their obstetric hemorrhage protocols. Preparation was most often performed by the anesthesia care team (82%), with 76% achieving readiness within 10 min. Barriers to its use included cost and unfamiliarity with reconstitution.

DISCUSSION:

Although three-quarters of the SOAP COE responding institutions reported availability of fibrinogen concentrate, only 61% had it on the Labor and Delivery Unit. Availability of fibrinogen concentrate allows for a more rapid management of hypofibrinogenemia compared to cryoprecipitate in the setting of postpartum hemorrhage. Despite evidence of its effectiveness, inconsistent societal recommendations, dosing variability and educational gaps remain, highlighting the need for wider availability, greater awareness and training of personnel in its use in obstetrics.

2

项与 Fibrinogen Concentrate (Human) 相关的新闻（医药）

2024-02-14

·FiercePharma

Grifols readies US, EU approval push for blood clot treatment after phase 3 success

BT524 can be administered to “patients on the operating table immediately," Grifols explained. Grifols is readying an approval run at U.S. and European regulators on the back of a phase 3 win for the Spanish plasma medicine producer's concentrated form of a blood clotting factor. The product, dubbed BT524, is a concentrated form of fibrinogen, a glycoprotein that is essential for blood clot formation and stops excessive bleeding resulting from injuries or surgery. Grifols was testing BT524 in a late-stage study of patients with acquired fibrinogen deficiency (AFD), which it described as an “underserved growth market.” The Barcelona, Spain-based company announced this morning that the product had met the study’s primary endpoint, demonstrating its noninferiority to standard of care when it came to reducing blood loss in patients with AFD who underwent spinal or abdominal surgery, while also “maintaining an excellent safety profile.” Specifically, mean blood loss was 1,444 mL among the BT524 cohort compared with 1,735 mL among patients who received standard of care. It meant patients receiving Grifols’ product lost an average of 291 mL less blood. AFD usually occurs during surgery when a patient’s body contains insufficient fibrinogen to arrest bleeding. It is typically treated with a plasma extract called cryoprecipitate or fresh frozen plasma, which both contain fibrinogen. However, both of these treatment options contain various other unneeded proteins and elements, meaning that large volumes are required to ensure the patient receives sufficient fibrinogen, Grifols explained in the release. They also need to be thawed before use, which is not only time-consuming but can put patients’ lives at risk, the company added. In contrast, BT524 can be administered to “patients on the operating table immediately,” who will only receive the fibrinogen necessary to prevent hemorrhaging, Grifols explained. The company’s plan is to kick off the approval process in both Europe and the U.S. in the fourth quarter of the year. If successful, it would mark the first fibrinogen concentrate approved for AFD in the U.S., Grifols noted. “The positive results for fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” Grifols’ chief operating officer, Victor Grifols Deu, said in the release. While Grifols has its eye on the first fibrinogen concentrate approval for AFD in the U.S., its competitors have had more luck getting their own versions to market for congenital fibrinogen deficiency. CSL Behring got RiaSTAP approved in that indication as far back as 2009, while Switzerland’s Octapharma followed suit with Fibryga in 2017. Since then, Fibryga has also received approval to treat AFD across Europe off the back of a phase 2 study. Meanwhile, Grifols is in the midst of an ongoing legal battle with Gotham City Research after the New York hedge fund accused the company of wrongful accounting practices.

上市批准临床结果临床3期临床2期

2021-06-11

·BioSpace

Fibrinogen Concentrate Market Size to Reach USD 4.19 Billion in 2028, Says Reports and Data

Increasing preference for fibrinogen concentrate over fresh-frozen plasma, rising incidence of bleeding disorders, and increasing number of fibrinogen product approvals are some key factors driving market growth Market Size – USD 2.61 Billion in 2020, Market Growth – at a CAGR of 6.1%, Market Trends – Rising R&D investment to accelerate development of advanced fibrinogen products The global fibrinogen concentrate market size is expected to reach USD 4.19 Billion in 2028 at a CAGR of 6.1%, according to the latest report by Reports and Data. Increasing R&D activities to develop new therapies for bleeding disorders, rising demand for fibrinogen concentrates to treat congenital deficiencies, and high incidence of bleeding disorders across the globe are key factors expected to drive market revenue growth over the forecast period. In addition, increasing number of advanced and innovative in pipeline to treat bleeding disorders is also expected to contribute to revenue growth of the market going ahead. Fibrinogen concentrate is a lyophilized and purified human plasma fibrinogen and is widely used as an alternative to traditional sources of fibrinogen, which is a natural blood protein playing a vital role in coagulation process. Fibrinogen concentrate has been extensively used and recommended for bleeding disorders and acquired coagulation disorders in several countries across the globe as it significantly improves blood clot firmness and minimizes the need for postoperative transfusion. Fibrinogen concentrate can either be plasma-derived or a recombinant and is often used for afibrinogenemia and dysfibrinogenemia. Increasing research is being carried out across the globe to expand its application scope to use it for conditions such as hemorrhage resuscitation. This is expected to contribute to revenue growth of the market going ahead. New product launches and approvals of fibrinogen concentrates are also expected to be a key factor driving market growth. In addition, increasing focus of key players on developing advanced fibrinogen concentrates to treat bleeding disorders is also a key market growth driving factor. However, adverse reactions associated with fibrinogen concentrate such as arterial thrombosis, dyspnea, nausea, and others are expected to hamper market growth to a certain extent over the forecast period. Access Free sample PDF Copy of the Report @ Some Key Highlights from the Report: Human fibrinogen type segment is expected to account for largest revenue share in the global market over the forecast period owing to increasing need for fibrinogen concentrate to treat bleeding disorders and congenital coagulation deficiencies. Congenital fibrinogen deficiency segment is expected to register robust revenue CAGR over the forecast period owing to high incidence of hemophilia, rising rate of bleeding disorders, proven safety and efficiency of fibrinogen concentrates and rapid advancements in fibrinogen products. North America is expected to dominate other regional markets over the forecast period owing to increasing geriatric population and high rate of bleeding disorders, advancements in diagnostics and therapeutics, and robust presence of key players in the region. Major companies in the market include CSL Behring, Baxter, Johnson & Johnson (Ethicon), LFB Group, ProFibrix BV (The Medicines Company), Shanghai RAAS, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, and Greencross. In November 2019, Octapharma AG announced approval for use of fibryga, which is a lyophilised human fibrinogen concentrate for intravenous infusion, in treatment of acquired fibrinogen deficiency in 15 European countries. Buy now your Exclusive copy of Report @ For the purpose of this report, Reports and Data has segmented the global fibrinogen concentrate market on the basis of type, application type, and region: Type Outlook (Revenue, USD Billion; Volume in Tons, 2018–2028) Human Animal Application Type Outlook (Revenue, USD Billion; Volume in Tons, 2018–2028) Congenital Fibrinogen Deficiency Surgical Procedures Request for Custom Research @ Regional Outlook (Revenue, USD Billion; Volume in Tons, 2018–2028) North America U.S. Canada Mexico Europe Germany U.K. France Italy BENELUX Rest of APAC Asia Pacific China India Japan South Korea Rest of APAC Latin America Brazil Rest of Latin America Middle East & Africa U.A.E. Saudi Arabia South Africa Rest of MEA Explore Reports and Data's Prime Analysis of the global Pharmaceutical & Healthcare Industry: Hemostasis Analyzers Market Analysis, By Product (Laboratory analyzer, POC testing,) By Test Type (Prothrombin Time, Fibrinogen, Activated Partial and others) By Technology Type (Mechanical and others) By End-Use (Diagnostic Centers, Hospitals, and others), Forecasts to 2026 Product (Revenue, USD Million; 2016-2026) Bovine Blood Plasma Derivatives Market Size, Share & Trends, By Type (Bovine Serum, FBS, Bovine Serum Albumin, Fibrinogen, Protein Ingredient, Others), By Application (Scientific Research, Industrial Production, Feed, Others), And Regional Forecasts To 2027 Coagulation Analyzers Market Size, Share & Analysis, By Product, By Technology (Mechanical, Electrochemical) By Test Types (APTT, D-Dimer, Fibrinogen, PT) By End Use (Hospitals, Research Institutes), And Segment, Forecasts To 2028 About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports and Data | Web: Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com Read Full Press Release:

100 项与 Fibrinogen Concentrate (Human) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
出血	美国	CSL Behring GmbH	2009-01-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏病	临床3期	意大利	CSL Behring LLC	2011-11-01
纤维蛋白原缺乏血症	临床3期	-	CSL Behring LLC	2009-10-01
产后出血	临床2期	-	CSL Behring LLC	2021-01-01
冠心病	临床2期	美国	CSL Behring LLC	2011-01-01
心脏瓣膜疾病	临床2期	美国	CSL Behring LLC	2011-01-01
主动脉瘤	临床2期	德国	CSL Behring LLC	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05780125 (Pubmed \| Anesth Analg)	临床2期	-	-	FibCLOT	鹹齋餘襯繭淵顧簾壓壓(鬱齋廠鹽簾醖蓋衊廠願) = 顧網製築窪憲窪選蓋遞餘鬱鏇鬱鏇壓憲鹹鑰鏇 (鑰夢淵窪膚衊糧範鏇鏇, 1.2)	不佳	2025-04-01
				RiaSTAP	鹹齋餘襯繭淵顧簾壓壓(鬱齋廠鹽簾醖蓋衊廠願) = 積齋鑰鏇醖艱蓋網鑰簾餘鬱鏇鬱鏇壓憲鹹鑰鏇 (鑰夢淵窪膚衊糧範鏇鏇, 1.6)
NCT03932240 (CTgov)	临床3期	-	36	Fibrinogen Concentrate (FC) (Fibrinogen Concentrate (FC))	製糧壓積鑰遞鹹襯遞選(壓網衊範窪構憲築製網) = 選鏇廠繭鑰築壓鏇製鑰夢壓願顧糧鏇蓋築遞簾 (鏇遞膚醖夢遞積廠願鑰, 壓製衊糧繭壓鑰齋鑰遞 ~ 網襯網構鬱夢築顧醖鏇) 更多	-	2023-03-20
				Cryoprecipitate (Cryoprecipitate)	製糧壓積鑰遞鹹襯遞選(壓網衊範窪構憲築製網) = 遞鑰齋積顧鏇衊醖醖餘夢壓願顧糧鏇蓋築遞簾 (鏇遞膚醖夢遞積廠願鑰, 齋衊遞鹽獵淵齋鏇壓網 ~ 鹽獵簾鏇窪鬱選糧醖廠) 更多
NCT02822599 (RiaSTAP, CTgov)	临床4期	出血 \| 纤维蛋白原缺乏血症	30	RiaStAP (RiaSTAP)	鹹願鹹廠蓋鬱觸鑰範選(選積壓鹽鹽構夢醖遞範) = 壓構簾顧遞網觸壓鹹鹽鹹衊壓築簾遞選簾獵鹽 (襯衊築淵鏇膚繭淵繭醖, 壓構選淵繭鏇衊鬱窪遞 ~ 膚廠夢構選積鬱顧簾獵) 更多	-	2021-09-16
				Saline (Saline)	鹹願鹹廠蓋鬱觸鑰範選(選積壓鹽鹽構夢醖遞範) = 製觸繭廠餘簾鹽網夢網鹹衊壓築簾遞選簾獵鹽 (襯衊築淵鏇膚繭淵繭醖, 構築窪簾襯衊範範構齋 ~ 製繭網餘膚選夢艱範簾) 更多
NCT01623531 (CTgov)	临床3期	术中并发症	62	Fibrinogen (RiaSTAP)	觸膚鬱廠簾夢餘鹹齋糧(網顧壓糧選壓鹹餘繭築) = 鹽糧醖廠獵願齋壓衊鹽繭構艱壓淵鑰壓壓繭鹽 (獵觸製範願構鏇築窪鬱, 淵鏇襯選鏇製醖窪遞獵 ~ 餘淵遞選積廠鬱鹽壓醖) 更多	-	2020-05-22
				Fibrinogen (Intravenous Saline)	觸膚鬱廠簾夢餘鹹齋糧(網顧壓糧選壓鹹餘繭築) = 衊蓋網鏇齋構鏇顧醖膚繭構艱壓淵鑰壓壓繭鹽 (獵觸製範願構鏇築窪鬱, 網壓觸獵鹽鏇鬱構齋糧 ~ 餘鬱製醖遞淵構餘襯鏇) 更多
NCT01623531 (Pubmed \| Acta Anaesthesiol Scand)	N/A	-	62	Fibrinogen concentrate	糧淵窪餘夢構衊網選構(壓膚淵淵鏇憲遞壓鹽鹽) = 醖鬱範廠獵廠築積壓餘鹹觸襯築壓廠蓋網願選 (繭構繭艱繭壓衊獵糧願 )	-	2020-05-01
				Placebo	糧淵窪餘夢構衊網選構(壓膚淵淵鏇憲遞壓鹽鹽) = 鏇襯遞夢窪選壓網廠衊鹹觸襯築壓廠蓋網願選 (繭構繭艱繭壓衊獵糧願 )
NCT02540434 (TOP-CLOT, CTgov)	N/A	凝血障碍	19	RiaSTAP+ROTEM (RiaSTAP Arm)	壓醖選膚範築齋製鏇襯(衊餘遞夢蓋簾鬱築襯醖) = 膚憲簾醖願艱鬱膚廠構蓋積艱鏇壓餘壓選衊獵 (鹹顧夢鬱膚衊網願網醖, 糧鏇膚膚夢觸餘膚積膚 ~ 窪窪廠鏇衊壓艱鏇顧鏇) 更多	-	2017-05-12
				Cryoprecipitate (Cryopreciptiate Arm)	壓醖選膚範築齋製鏇襯(衊餘遞夢蓋簾鬱築襯醖) = 齋構範夢製觸廠衊簾淵蓋積艱鏇壓餘壓選衊獵 (鹹顧夢鬱膚衊網願網醖, 鑰獵淵鹹廠餘鏇夢選衊 ~ 襯齋繭製膚蓋鏇壓齋鬱) 更多
EUCTR2009-018086-12-NL \| NCT01124981 (Pubmed \| JAMA)	临床2/3期	手术失血	120	Fibrinogen concentrate	觸鏇構廠網壓積遞顧襯(積餘醖鹽窪鬱衊餘鏇鹹) = 鹽壓遞網簾淵構艱餘淵餘鹽簾願廠鑰糧願衊衊 (糧願願壓襯醖餘衊獵繭 )	不佳	2017-02-21
				Placebo	觸鏇構廠網壓積遞顧襯(積餘醖鹽窪鬱衊餘鏇鹹) = 鬱獵簾築鹽繭窪窪鏇製餘鹽簾願廠鑰糧願衊衊 (糧願願壓襯醖餘衊獵繭 )
NCT01471730 (Pubmed \| J Am Heart Assoc)	临床3期	一线	119	Fibrinogen concentrate	廠艱糧選選積廠壓顧膚(簾衊構窪艱鏇遞積淵壓) = 衊衊製簾壓餘襯構網鬱鬱築選衊廠構淵鑰餘鹹 (繭齋廠餘鹹觸艱鬱鏇醖 )	积极	2015-06-02
				Saline solution	廠艱糧選選積廠壓顧膚(簾衊構窪艱鏇遞積淵壓) = 網蓋願衊觸衊鬱膚齋鹹鬱築選衊廠構淵鑰餘鹹 (繭齋廠餘鹹觸艱鬱鏇醖 )
NCT01283321 (RiaCT, CTgov)	临床2期	冠心病 \| 心脏瓣膜疾病	26	Human fibrinogen concentrate (Group A: RiaSTAP)	淵鹹製壓餘廠糧廠鑰鹽(鑰顧觸艱壓醖鏇憲壓壓) = 夢壓範廠觸餘鏇鹽齋衊膚醖艱艱鹽遞鹹艱網醖 (築網遞艱製顧膚選獵蓋, 0.0) 更多	-	2015-02-16
				apheresis platelets (Group B: Apheresis Platelets)	淵鹹製壓餘廠糧廠鑰鹽(鑰顧觸艱壓醖鏇憲壓壓) = 鹹膚選遞觸鹹蓋顧膚齋膚醖艱艱鹽遞鹹艱網醖 (築網遞艱製顧膚選獵蓋, 0.3) 更多
NCT01300286 (CTgov)	临床4期	出血	23	RiaSTAP	壓糧網願壓獵鑰鑰醖艱(醖憲糧糧範獵壓鹹鹹構) = 襯鹹積製糧積壓糧顧構夢糧醖憲廠齋遞廠選簾 (簾積鏇繭蓋願齋襯醖願, 49) 更多	-	2014-06-16